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Summary
Urokinase plasminogen activator (uPA) and its inhibitors (PAI) are elements of pla-
sminogen activation system, a proteolytic system involved in many physiological and pa-
tological processes. In this paper their induction by etoposide, a topoisomerase II inhibitor,
in A1235 glioblastoma cell strain is described. Etoposide induced uPA and PAI produc-
tion, in a dose- and time-dependent manner. Induction was based on the activation of the-
ir promoters and extracellular proteolysis was dependent on their equilibrium. Etoposide
caused p53 activation and p21 and gadd45 induction, which could be responsible for the
cell growth arrest. Our data indicate that several pathways could be involved in the uPA
and PAI induction.
Key words: urokinase, plasminogen activator inhibitor, uPA promoter, PAI promoter, eto-
poside, glioblastoma cell strain
Introduction
Urokinase-type plasminogen activator (uPA) is high-
ly specific serine protease involved in the regulation of
many normal and malignant processes, participating in
tissue remodelling, migration and invasion (1). It is also
involved in non-proteolytic signalling events leading to
adhesion and chemotaxis (2). uPA converts plasminogen
to plasmin, which further degrades extracellular matrix
and activates latent collagenases. The ubiquitous and
with wide-spectrum of substrates, plasmin could be
dangerous as a protease if not tightly controlled through
plasminogen activator activation. Plasminogen activation
system has a multistep control through uPA gene tran-
scription, protein production, localized activation, as
well as its inhibition and degradation (3). uPA is secre-
ted as a single-chain proenzyme and converted by lim-
ited proteolysis into an active two-chain molecule. Ac-
tive uPA can bind to its cell surface receptor (PAR), and
to its inhibitors, PAI-1 and PAI-2. uPA-PAI complex
bound to receptor is internalized and degraded (4).
Plasminogen activation system is closely associated
with tumour invasiveness and metastasis by virtue of its
biological properties, and uPA and PAI were found to
be overregulated in tumour or neighbouring cells (3).
Both of them can be induced with a number of growth
factors, hormons, oncoproteins, cytokines, but also with
some tumour promoters and carcinogens (5–9), all of
them activating specific signal transduction pathways.
In certain cell lines uPA induction was shown to be con-
nected with unrepaired DNA damage: methyl-nitroso
urea and N-methyl-N'-nitro-N-nitroso-guanidine caused
uPA induction in alkylation-repair deficient cell strains
(10) and low UV influences in xeroderma pigmentosum
DNA repair-deficient human cells (11). In this context it
was interesting to analyse plasminogen activation sys-
tem in A1235 glioblastoma cell strain after treatment
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with topoisomerase II inhibitor etoposide (12). This
widely used anticancer drug poisons the topoisomerase
II, induces double strand breaks and causes mutagenic
and lethal events. Here we show that it can also induce
uPA and PAI production in a dose-dependent manner.
Used as chemotherapeutics, etoposide could induce sim-
ilar processes in vivo.
Material and Methods
Plasmids, cells and chemicals
Plasmid 5.5kb-uPACAT, containing human 5.5 kb
uPA promoter fused to the CAT gene and PAI-1CAT,
containing 633 bp long human PAI-1 promoter, were
obtained from Dr Y. Nagamine (Friedrich Miescher In-
stitute, Basel, Switzerland). Plasmid pHUL45B2, contain-
ing gadd45 gene was a kind gift from Dr A. Fornace
(NCI, NIH, Bethesda, MD). Plasmid phPAI-1 05, used
for a hybridization probe, was a kind gift from Dr P.
Autzen Usher and Dr K. Dano (Finsen Laboratory, Co-
penhagen, Denmark), and pNATCAT, containing hu-
man PAI-2 promoter from Dr T. M. Antalis (Queensland
Institute of Medical Research, Brisbane, Australia).
Plasmids were purified by alkaline lysis method as de-
scribed previously (13).
Human glioblastoma cell line A1235, obtained from
S. A. Aaronson (NCI, NIH, Bethesda, MD), and its
transfectants were cultivated in DMEM (Sigma Chemi-
cals, St. Louis, MO) supplemented with 10 % fetal bo-
vine serum (Gibco Life Technologies, UK) and antibiot-
ics, at 37 °C and 5 % CO2. Cell counts were performed
by Coulter Counter.
Antibodies
p53 antibodies, provided by Dr L. Banks (ICGEB,
Trieste, Italy), were obtained from conditioned media of
three clones producing monoclonal antibodies (pAB1801,
pAB1802, pAB1803) (14). Monoclonal mouse antibody
p21 (WAF 1/Ab-1) was supplied from Oncogene Re-
search Product Calbiochem, La Jolla, CA and human
uPA monoclonal mouse antibody from American Diag-
nostica, US.
Chemicals and enzymes
Human urokinase was purchased from Calbiochem
and human plasminogen from KabiVitrum (Stockholm,
Sweden). D-threo-dichloroacetyl-1-14CChloramphenicol
was purchased from Amersham (UK) and acetyl coen-
zime A from Boehringer Meinheim (Germany). Adria-
mycin was supplied from Farmitalia Carlo Erba, Italia.
Etoposide (Etopol, Krka, Novo Mesto, Slovenia) was
dissolved in physiological solution.
Transfection and CAT assay
A1235 cells transfected with 5.5 kb-uPACAT plasmid,
were described previously (15). PAI-1CAT and PAI-
-2CAT clones were obtained by stable transfection with
PAI-1CAT and pNATCAT plasmids, respectively, using
Superfect Transfection Reagent (Qiagen, Germany). Dur-
ing the experiment, cells were treated with etoposide for
24 h and incubated in the drug-free medium for addi-
tional 24 h when cell extracts were collected. Cell extracts
were prepared and assayed for the chloramphenicol
acetyltransferase (CAT) activity according to a standard
procedure (13). Briefly, the same amount of cellular ex-
tracts was incubated with 266 M acetyl coenzyme A
and 0.5 Ci 14Cchloramphenicol for 1–1.30 h at 37 °C,
and after the ethyl acetate extraction separated by thin-
-layered chromatography. After the exposure, bands on
X ray film were analysed by Image Master VSD Soft-
ware (Pharmacia Biotech, Uppsala, Sweden).
PAGE and Western blot
Total cell extracts were prepared using lysis buffer
(50 mM Tris HCl pH=8.0, 150 mM NaCl, 0.02 % Na azide,
100 g/mL phenylmethylsulfonyl fluoride (PMSF), 1 %
Triton X-100) and protein concentration was determined
according to Bradford (13). Protein samples were mixed
with the loading buffer, boiled at 95 °C for 5 min (for
denaturing conditions), loaded on a 12 % SDS-PA gel
and electrophoresed as described previously (13). Pro-
teins were transferred onto nitrocellulose membrane
(Hybond, Amersham) in transfer buffer (25 mM Tris
HCl pH=8.3, 192 mM glycin, 20 % methanol), employ-
ing Hoefer (Amersham-Pharmacia) transblot apparatus.
Blots were blocked overnight in PBST (0.1 % Tween-20
in phosphate buffered saline) containing 5 % nonfat
dried milk and incubated with primary antibodies to
p53 or p21 for 1–2 h. As a secondary antibody biotinyl-
ated goat-antimouse IgG (Oncogene Research Products,
Calbiochem) was used, followed by incubation with
streptavidin, H2O2 and 3.3'-diaminobenzidine (DAB)
(13). For uPA analysis, conditioned media were concen-
trated using Microcon 10 tubes (Amicon, USA). Gels
were run under nondenaturing conditions, membranes
blocked in TBST (0.5 % Tween-20 in Tris buffered sa-
line) containing 5 % nonfat dried milk and primary
mouse uPA antibody was used (American Diagnostica,
USA). For detection, ECL system (Amersham) was em-
ployed.
Plasminogen activator and plasminogen activator
inhibitor activity analysis
uPA activity was assayed by radial caseinolysis in
the conditioned, serum-depleted media from etoposide
treated A1235. Medium aliquotes were added to the
wells made on the 1 % agarose plate containing 2.5 %
nonfat powdered milk, 0.1 % sodium azide and 5 g/mL
human plasminogen. Diameters of clear areas were
measured after incubation at 37 °C for 24 h and uPA ac-
tivity estimated by interpolation from a calibrated curve
of human urokinase (16).
PAI-1 activity was assayed by reverse casein zymo-
graphy. Exponentially growing A1235 cells were treated
with etoposide or adriamycin for 24 h, when medium
was replaced for the serum- and drug-free one, for addi-
tional 10 h. The conditioned media were collected and
concentrated by centrifugation in Centricon 30 tubes.
Cell lysates were prepared as previously described (17),
and the amount of protein determined according to
Bradford (13). Volumes of conditioned media were nor-
malized and run on 12 % polyacrylamide gel under
nondenaturing conditions. After electrophoresis gels
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were incubated in 2.5 % Triton X-100 for 2–3 h and rin-
sed in water for 1 h. For uPA detection gel was put on
casein underlay (1 % agarose, 3–4 % non fat milk, so-
dium azide and 12.5 g/mL human plasminogen) (10).
For PAI-1 detection parallel gel was put on casein un-
derlay containing 0.05 U/mL human urokinase (18).
Gels were incubated for 24 h at 37 °C and photograp-
hed.
RNA extraction and Northern blot analysis
Total RNA was extracted from cultured cells as pre-
viously described (19). RNA samples were separated by
agarose gel electrophoresis, capillary transferred to a ny-
lon membrane (Roche Molecular Biochemicals, Ger-
many) overnight, and crosslinked with UV. For gadd45
detection, the membrane was hybridized at 65 °C over-
night with the probe labelled with [32P] by random
priming reaction and exposed to X-ray film at –70 °C.
For PAI-1 detection, the membrane was hybridized at 65
°C overnight with the probe labelled with digoxigenin
by random priming reaction, according to manufac-
turer's manual (DIG DNA labeling and detection kit,
Roche Molecular Biochemicals). Detection was per-
formed using CDP-Star chemiluminescence substrate
(Roche Molecular Biochemicals). X ray films were analy-
sed by Image Master VSD Software.
Results
Etoposide enhances uPA, PAI-1 and PAI-2 promoter
activity
We examined the effects of etoposide on the pro-
duction of urokinase and its inhibitors (PAI-1 and
PAI-2) in A1235 cells by analysing their promoter activi-
ties. Cells permanently transfected with either 5.5 kb
uPA promoter-CAT or PAI-1 promoter-CAT or PAI-2
promoter-CAT plasmids were treated with different
concentrations of etoposide for 24 h, incubated in the
drug-free medium for additional 24 h and analysed for
CAT activity. As shown in Fig. 1, uPA, PAI-1 and PAI-2
promoters were all activated by etoposide treatment in a
dose-dependent manner.
Etoposide induces uPA and PAI-1 production
To determine whether etoposide-induced uPA and
PAI promoter activities are accompanied with extra-
cellular urokinase production, A1235 cells were exposed
to a 2.5–10 M concentration range of etoposide for 6, 12
or 24 h in the serum-free medium and the excreted uPA
analysed by Western blots and caseinolysis. As illus-
trated in Fig. 2A and 2B, etoposide induced several-fold
control level of uPA production in a dose- and time-de-
pendent manner, when assayed by Western blotting.
The extracellular uPA of both etoposide-treated and un-
treated cells comigrated with commercial 55 kDa and, in
some samples, with 30 kDa human urokinase; a band of
approximately 90–100 kDa was also observed, apparent-
ly induced in a dose- and time-dependent manner.
Radial caseinolysis performed with the same sam-
ples revealed that a 24-hour exposure of A1235 cells to 5
M etoposide enhanced 5-fold control level of uPA ac-
tivity, whereas 10 M etoposide enhanced uPA activity
only 2-fold (Fig. 2C). These findings are of interest for
two reasons: (i) drop in uPA activity that was observed
at 10 M etoposide coincided with the accumulation of
the slow moving 90–100 kDa band (Fig. 2A and 2B) (ii)
this band could represent a complex between uPA and
its inhibitors, PAI-1 or PAI-2 (20). Since net uPA activity
is also determined by PAI-activity (21,22), we studied
the effect of etoposide on PAI-1 production in A1235
cells. The cells were treated with 10 M etoposide for 2,
6, 12 and 24 h, when total RNA was extracted and sub-
jected to Northern blot analysis, using digoxigenin la-
belled PAI-1 probe. As shown in Fig. 3, etoposide in-
duced several-fold control level of two PAI-1 RNA spe-
cies (2.4 kb and 3.4 kb) in a time-dependent manner
(23).
To further evaluate etoposide mediated induction of
PAI-1 mRNA, the effect on the extracellular PAI-1 pro-
duction was also examined. The cells were treated with
either 5 M etoposide or 2.5 M adriamycin (which is
also a topo II inhibitor and was used here as a positive
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Fig. 1. Etoposide enhances uPA, PAI-1 and PAI-2 promoter activity. A1235 cells were permanently transfected with human 5.5 kb
uPA promoter-CAT reporter plasmid (A), PAI-1 (B) and PAI-2 promoter CAT reporter plasmids (C). Cells were treated with diffe-
rent etoposide concentrations for 24 h, washed and incubated for additional 24 h in the drug-free medium, when cell extracts were
collected and CAT assay performed. Numbers below figures represent percentage of chloramphenicol conversion (CAT activity).
control) for 24 h and incubated in the serum depleted
medium for additional 10 h. Conditioned media were
collected, electrophoresed and subjected to reverse gel
zymography using either the casein-plasminogen under-
lay (for uPA detection) or the casein-plasminogen-uroki-
nase underlay (for PAI-1 detection). Zymography revea-
led strong uPA lysis zones in the samples obtained from
etoposide and adriamycin treated cells, as compared
with untreated control (Fig. 4A), indicating that both
topo II inhibitors induced high levels of uPA. Zymogra-
phic analysis of the same samples using casein-plasmi-
nogen-urokinase underlay showed unlysed zones just
below urokinase bands (Fig. 4B), indicating the presence
of increased amounts of PAI-1 in the samples obtained
from the drug-treated cells. PAI-2 could not be detected
by this method due to its instability (24).

























Fig. 2. Etoposide induces extracellular uPA production. A1235
cells were treated with 5 and 10 M etoposide for 6, 12 and 24
h (A) or with 2.5, 5 and 10 M etoposide for 24 h (B), in the se-
rum depleted medium. At indicated time points conditioned
media were collected, concentrated and subjected to Western
blot analysis (A and B) or radial caseinolysis (C). As internal
molecular weight standard, commercial human urokinase was
used (U).
Fig. 3. Etoposide induces PAI-1 mRNA. A1235 cells were trea-
ted with etoposide for 2, 6, 12 and 24 h, when total RNA was
isolated, transferred on the nylon membrane and hybridized
with digoxigenin labelled PAI-1 probe. Detection was perfor-
med by chemiluminiscence reaction. A. Northern blot: c, con-
trol; 2, 2 h etoposide treatment; 6, 6 h treatment; 12, 12 h treat-
ment; 24, 24 h treatment. B. Gel stained with ethidium bro-
mide. Numbers below figure represent relative intensity of the
bands.
Fig. 4. Etoposide induces uPA and PAI-1 activity. Cells were
treated with 5 M etoposide or 2.5 M adriamycin for 24 h,
and incubated in the medium without serum for additional 10
h when conditioned medium was collected, concentrated, nor-
malized, and analysed by PAGE. The gel was incubated at 37
°C for 24 h on the second indicator gel containing either human
plasminogen (A), or human plasminogen and 0.05 U/mL uro-
kinase (B) for PAI-1 detection. c, control; ad, 2.5 M adriam-
ycin; et, 5 M etoposide; ur, 0.01 U/L urokinase. Numbers be-
low the gel represent relative intensity of the bands.
Fig. 5. Effect of etoposide on the growth of A1235 cells. Cells
were treated with indicated concentrations of etoposide for 24
h and incubated in the drug-free medium until the end of the
experiment. Cell number was determined electronically at daily
intervals.
Etoposide stabilizes p53 and induces gadd45 and p21
In the view of the above observations it was desir-
able to obtain information concerning the effect of eto-
poside on the cell growth under the treatment condi-
tions that caused uPA and PAI induction. uPA and PAI
induction occurred at etoposide concentrations of 2.5–5
M which caused cell growth arrest, but without ob-
viuos cell dying (Fig. 5). However, etoposide at concen-
trations above 10 M and after prolonged treatment (e.g.
50 h) caused apoptosis (data not shown).
Since etoposide is known to cause p53 stabilization
and p53-dependent p21 and gadd45 induction, we wan-
ted to determine whether genes that are involved in cell
growth arrest and apoptosis (12,25) could also be indu-
ced in A1235 cells. Extracts were prepared from cells
treated for 4 h with 5 M etoposide or 5 M adriamycin
(a positive control) (12) and subjected to Western blot
analysis. As shown in Fig. 6A and 6B, etoposide and
adriamycin induced high levels of both p53 and p21 as
compared to the untreated controls. As gadd45 is often
induced by p53 and is also involved in the growth ar-
rest (26), RNA prepared from the cells treated with 5
M etoposide or 5 M adriamicin for 10 h was analysed
by Northern blot. As shown in Fig. 6C, gadd45 gene was
strongly induced in the treated cells.
Discussion
Plasminogen activation system involves several ge-
nes which play an important role in biological processes
and thus are regulated through the whole net of signal
transduction pathways. We examined the ability of eto-
poside, topoisomerase II inhibitor, to induce the produc-
tion of uPA, PAI-1 and PAI-2 in A1235 glioblastoma cell
strain. The data show that etoposide induced uPA and
PAI in a dose- and time-dependent manner, and that
this induction was based on the activation of respective
promoters. Western blot analysis showed that conditio-
ned media of etoposide-treated cells, beside 30–55 kDa
urokinase species, contain a slow moving 90–100 kDa
form, which coincided with a drop of uPA activity (Fig.
2). Since etoposide also induced PAI production in
A1235 cells, it was assumed that this band could repre-
sent a complex between uPA and its inhibitors (23,27).
This could be reconciled with the observation that net
uPA activity is also determined by PAI activity (21,22).
Etoposide is widely used as chemotherapeutic drug
and many mechanisms of its action are known (12). As a
topoisomerase II poison, it makes DNA adducts and
stops DNA polymerase, and as a consequence, double
strand breaks can occur. In response to DNA damage,
p53 is activated and ATM kinase recruited. p53 effects
cell cycle arrest after activating p21, gadd45 and mdm2
genes to allow DNA repair to take place (26,28). We
showed that etoposide activated p53 and induced p21
and gadd45 in A1235 cells that could cause observed cell
growth arrest of treated cells. Only doses higher than 10
M or prolonged treatment probably activate p53-de-
pendent pathways connected with apoptosis, as in the
case of unsuccessful repair (28). In comparison with
other topo II inhibitors, etoposide is specific for induc-
tion of significant dose-dependent DNA damage and
double strand breaks at concentrations that do not affect
cell survival (29).
p53 could be connected with PAI-1 induction after
etoposide treatment. PAI-1 promoter contains p53 bind-
ing site responsible for PAI transcription after p53 over-
expression (30). Etoposide induced PAI-1 expression co-
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Fig. 6.A. Etoposide activates p53. A1235 cells were treated with
5 M etoposide or 5 M adriamycin for 4 h when they were
collected, extracts prepared and analysed by Western blotting
with p53 antibody.
c, control; et, 5 M etoposide; ad, 5 M adriamycin.
a. Membrane immunoblotted with p53 antibody and stained
with biotin-horseradish peroxidase-DAB. b. Coomassie blue
stained gel.
Fig. 6.B. Etoposide and adriamycin induce p21. Experimental
conditions were as in Fig. 6A, except that p21 antibody was
used.
c, control; et, 5 M etoposide; ad, 5 M adriamycin.
a. Membrane immunoblotted with p21 antibody and stained
with biotin-horseradish peroxidase-DAB. b. Coomassie blue
stained gel. Numbers above the figures represent induction fac-
tors relative to the control, as determined by densitometry.
Fig. 6.C. Etoposide and adriamycin induce expression of gadd45
mRNA in A1235 cells. A1235 cells were treated with 5 M eto-
poside or 5 M adriamycin for 10 h, when total RNA was ex-
tracted, electrophoresed and subjected to Northern blot anal-
ysis. The membrane was hybridized with [32P]gadd45 and
autoradiographed.
c, control; et, etoposide; ad, adriamycin.
a. Northern blot hybridized with gadd45 probe.
b. Gel stained with etidium bromide.
Numbers below the gels represent relative intensity of the
bands.
incided with p53 activation. Considering uPA induction,
Kunz showed that overregulation of p53 can inhibit
uPA transcription, although the mechanism is still un-
known (30). Therefore, the pathways leading to etopo-
side induced uPA production could be different. uPA
induction is usually connected with several signaling
pathways; the best known are those involving TPA and
protein kinase C activation, phosphatase inhibition or
cytoskeletal disruption (5,9,31–33). The last step usually
includes AP-1 activation and binding of transcription
factors to one or both of AP-1 sites on the uPA promo-
ter. Etoposide was found to induce JNK and c-jun phos-
phorylation and protein kinase C activation (34–36). In
the most cell lines its action was examined in the con-
text of apoptosis: the role of c-jun was found to be cell
type specific and different apoptotic pathways were
found to operate in different cell lines (35,37,38). We ob-
served up to two-fold activation of the TRE promoter
(containing 5xAP-1 binding sequence) by etoposide and
adriamycin treatment (data not shown). On the other
side, curcumin (AP-1 inhibitor) (39) did not inhibit
etoposide-induced uPA promoter in A1235 cells (data
not shown). AP-1 induction cannot always be corellated
with uPA induction: some strong inducers and up-
stream oncoproteins did not significantly change uPA
level (e.g. pyrrolidine dithiocarbamate) (15), and adri-
amycin, a strong AP-1 inducer and also topoisomerase II
inhibitor, did not show significantly stronger effect on
the uPA promoter activation in comparison with etopo-
side (data not shown). In addition, AP-1 elements are
present also in the PAI-1 and PAI-2 promoters (20,27),
and could contribute to their induction. Whether AP-1
activation is the mechanism of uPA promoter activation
or there are some other elements included, remains to
be elucidated.
uPA and PAI, as elements of plasminogen activa-
tion system, play a crucial role in the regulation of ex-
tracellular matrix degradation in cancer invasion and
metastasis. They are often upregulated in cancer or neigh-
bouring cells and could even be prognostic factors (40).
Concomitant expression of uPA and PAI was found to
increase in different cancer cell lines (40,41); oncogenic
stimuli may activate constitutively their upstream path-
ways (3). For instance, many tumour promoters and car-
cinogens are known as uPA and PAI inducers, TPA be-
ing one of the best studied (1,8,11,42). Carcinoma cells
treated chronically with increasing concentrations of
adriamycin, showed overregulation of PAI-1 level in
comparison with untreated (sensitive) cells (43). A1235
cells strongly expressed uPA after the treatment with al-
kylating agents, as they are defective in the repair of
that kind of damage (10). These cells also, treated with
cisplatin, produced increased levels of extracellular uPA
and PAI-1 (44).
In conclusion, our results suggest that etoposide in-
duced uPA and PAI production in A1235 glioblastoma
cells is based on the activation of their promoters and
probably associated with DNA damage dependent p53
activation. Since etoposide is a widely used chemothe-
rapeutic agent, these data indicate that similar processes
could occur in vivo.
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Indukcija urokinaznog tipa plazminogenskog aktivatora
i njegova inhibitora etopozidom u glioblastomskoj
stani~noj liniji A1235
Sa`etak
Urokinazni tip plazminogenskog aktivatora (uPA) i njegovi inhibitori (PAI) dijelovi su
plazminogenskog aktivacijskog sustava, proteoliti~kog sustava uklju~enog u mnoge fizio-
lo{ke i patolo{ke procese. U ovom je radu opisana njihova indukcija etopozidom, inhibito-
rom topoizomeraze II, u stanicama glioblastoma A1235. Etopozid je inducirao uPA i PAI
ovisno o koncentraciji i vremenu inkubacije. Indukcija je ovisila o aktivaciji njihova pro-
motora, a ekstracelularna proteoliza o njihovoj ravnote`i. Etopozid je uzrokovao aktivaciju
p53, kao i indukciju p21 i gadd45, te bi oni mogli biti odgovorni za zaustavljanje stani~nog
rasta. Rezultati upu}uju da bi nekoliko signalnih puteva moglo sudjelovati u indukciji
uPA i PAI.
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